AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31522845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0·2 mg vs Ranibizumab 0·1 mg
Number of subjects: 225
Study 31522845 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 225
Study 28440041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted catheter-directed thrombolysis (USAT)
Number of subjects: 48
Study 28440041 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter-directed thrombolysis (CDT)
Number of subjects: 48
Study 26554707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 134
Study 26554707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 134
Study 26554707 — intervention group
Group type: COMPARATOR
Intervention: Non-optimal treatment (CT or IPT)
Number of subjects: 134
Study 23708802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sensory error signal with a 30° rotated hand-cursor distortion
Number of subjects: 0
Study 23708802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sensory error signal with further increases (up to 70°)
Number of subjects: 0
Study 23708802 — intervention group
Group type: COMPARATOR
Intervention: Previous study with sensorimotor and cross-sensory errors
Number of subjects: 0
Study 20499362 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment in postmenopausal women for 4 weeks
Number of subjects: 76
Study 20499362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no estrogen treatment) in postmenopausal women (n = 18)
Number of subjects: 76
Study 20499362 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic testosterone and estrogen replacement in elderly men
Number of subjects: 76
Study 20499362 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of testosterone or estrogen in elderly men
Number of subjects: 76
Study 20499362 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with changes in bone-resorption markers
Number of subjects: 76
Study 19302912 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/paracetamol 375/300 mg per 15 mL suspension
Number of subjects: 52
Study 19302912 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/paracetamol 275/300 mg tablet
Number of subjects: 52
Study 17578313 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Qingre Huayu Recipe (JQH)
Number of subjects: 50
Study 17578313 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (Control)
Number of subjects: 50
Study 15114697 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administered twice daily at 80, 100 or 120 mg/body/day for 28 days followed by 14 days of rest
Number of subjects: 81
Study 15114697 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 81
Study 11263760 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic drugs for Alzheimer's disease
Number of subjects: 0
Study 11263760 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive tools for asymptomatic individuals
Number of subjects: 0
Study 9713009 — intervention group
Group type: COMPARATOR
Intervention: Thrice daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Number of subjects: 22
Study 9713009 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Number of subjects: 22
Study 8790516 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening for seven years
Number of subjects: 0
Study 8790516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography detection
Number of subjects: 0
Study 8790516 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE education
Number of subjects: 0
Study 8790516 — intervention group
Group type: COMPARATOR
Intervention: Comparison centres (non-screening)
Number of subjects: 0
Study 2928433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.14 mg/kg)
Number of subjects: 12
Study 2928433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31570034 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitored care
Number of subjects: 51
Study 31570034 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 31570034 — intervention group
Group type: COMPARATOR
Intervention: Phone-call care
Number of subjects: 51
Study 31734103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg
Number of subjects: 437
Study 31734103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg
Number of subjects: 437
Study 31734103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg
Number of subjects: 437
Study 31734103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 30131425 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate magnesium (2.0 mEq/L) for 28 days
Number of subjects: 59
Study 30131425 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate magnesium (1.0 mEq/L)
Number of subjects: 59
Study 30131425 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of T50 between groups at follow-up
Number of subjects: 59
Study 30131425 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of serum magnesium between groups
Number of subjects: 59
Study 28095807 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants on ART
Number of subjects: 165
Study 28095807 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants with virologic suppression and immune recovery at 6 months
Number of subjects: 165
Study 28095807 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants with poor 6-month post-ART responses (lacking viral suppression and immune recovery)
Number of subjects: 165
Study 26071057 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Number of subjects: 0
Study 26071057 — intervention group
Group type: COMPARATOR
Intervention: levamisole
Number of subjects: 0
Study 24264551 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 15 mg.kg‐1 dissolved in 10 ml of saline orally 30 min. before induction of anesthesia
Number of subjects: 46
Study 24264551 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of saline (Control)
Number of subjects: 46
Study 21342757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (3-month duration)
Number of subjects: 40
Study 21342757 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise training (3-month duration)
Number of subjects: 40
Study 19108793 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN FDC (10/5 mg, 20/10 mg, 40/20 mg)
Number of subjects: 62
Study 19108793 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone PR 40 mg + Naloxone PR 20 mg
Number of subjects: 62
Study 19108793 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN FDC 40/20 mg
Number of subjects: 62
Study 19108793 — intervention group
Group type: COMPARATOR
Intervention: Naloxone PR tablet 20 mg
Number of subjects: 62
Study 19108793 — intervention group
Group type: EXPERIMENTAL
Intervention: OXN, Oxycodone PR, Naloxone PR
Number of subjects: 62
Study 17017826 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 0
Study 17017826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 0
Study 12730793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 126
Study 10781448 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% alone, 1.0 mL/kg
Number of subjects: 60
Study 10781448 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with fentanyl 1 microg/kg
Number of subjects: 60
Study 9515228 — intervention group
Group type: EXPERIMENTAL
Intervention: JET spacer
Number of subjects: 5
Study 9515228 — intervention group
Group type: COMPARATOR
Intervention: pMDI without JET spacer
Number of subjects: 5
Study 8227450 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg meclofenamate sodium bid
Number of subjects: 22
Study 8227450 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg meclofenamate sodium bid
Number of subjects: 22
Study 8227450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3817239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithrocream
Number of subjects: 15
Study 3817239 — intervention group
Group type: COMPARATOR
Intervention: Dithranol in Lassar's paste
Number of subjects: 15
Study 31764461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise session (IES) involving large muscle mass: 8 sets × 1 min contraction at 30% maximal voluntary isometric contraction with 2‐min rest interval
Number of subjects: 24
Study 31764461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise session (IES) involving large muscle mass
Number of subjects: 24
Study 30998396 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided antiplatelet therapy
Number of subjects: 0
Study 30998396 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 28069009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy for 3 years
Number of subjects: 0
Study 28069009 — intervention group
Group type: COMPARATOR
Intervention: Room air delivered by a concentrator modified to deliver 21% oxygen (Control)
Number of subjects: 0
Study 26395439 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention (first stage focused on diet, physical activity, and screen-time behaviour)
Number of subjects: 1370
Study 26395439 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention (second stage focused only on diet and physical activity)
Number of subjects: 1370
Study 26395439 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1370
Study 23712446 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg betamethasone intravenously
Number of subjects: 398
Study 23712446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 22108475 — intervention group
Group type: EXPERIMENTAL
Intervention: External valvuloplasty with EVS
Number of subjects: 49
Study 22108475 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ligation or stripping)
Number of subjects: 49
Study 19576645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose concurrent chemo-radiation followed by surgery
Number of subjects: 0
Study 19576645 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemo-radiation
Number of subjects: 0
Study 12969087 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-erosive gastro-oesophageal reflux disease
Number of subjects: 65
Study 12969087 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-erosive gastro-oesophageal reflux disease with normal acid exposure time
Number of subjects: 65
Study 15613191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 27
Study 15613191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8672382 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 micrograms
Number of subjects: 38
Study 8672382 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 5 mg
Number of subjects: 38
Study 8672382 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 38
Study 8672382 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 38
Study 1665271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate 1600 mg daily
Number of subjects: 40
Study 1665271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6857109 — intervention group
Group type: EXPERIMENTAL
Intervention: (--) Eburnamonine
Number of subjects: 2
Study 6857109 — intervention group
Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 2
Study 3933810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine cleansing before bag application
Number of subjects: 62
Study 3933810 — intervention group
Group type: COMPARATOR
Intervention: No cleansing before bag application
Number of subjects: 62
Study 3933810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine cleansing
Number of subjects: 62
Study 3933810 — intervention group
Group type: COMPARATOR
Intervention: No cleansing
Number of subjects: 62
Study 3933810 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstream urine specimens
Number of subjects: 62
Study 3933810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bagged urine specimens
Number of subjects: 62
Study 28826957 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Port Laparoscopic Myomectomy (SP-LM)
Number of subjects: 66
Study 26478104 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-CMC (sodium hyaluronic acid-carboxymethylcellulose)
Number of subjects: 753
Study 24944137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3v3
Number of subjects: 12
Study 24944137 — intervention group
Group type: EXPERIMENTAL
Intervention: 5v5
Number of subjects: 12
Study 24944137 — intervention group
Group type: EXPERIMENTAL
Intervention: 7v7
Number of subjects: 12
Study 22561098 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy (mCIMT)
Number of subjects: 30
Study 22561098 — intervention group
Group type: COMPARATOR
Intervention: Bimanual task‐related training
Number of subjects: 30
Study 20148744 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0
Study 18400976 — intervention group
Group type: EXPERIMENTAL
Intervention: EP HIV-1090 (DNA vaccine)
Number of subjects: 32
Study 18400976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16022936 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person decisional balance (IDB)
Number of subjects: 131
Study 16022936 — intervention group
Group type: EXPERIMENTAL
Intervention: Written decisional balance (WDB)
Number of subjects: 131
Study 16022936 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (C)
Number of subjects: 131
Study 14640387 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg
Number of subjects: 108
Study 14640387 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 850 mg
Number of subjects: 108
Study 14640387 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study 11006052 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts Tobacco Control Program
Number of subjects: 0
Study 8648205 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccine
Number of subjects: 0
Study 8648205 — intervention group
Group type: COMPARATOR
Intervention: hepatitis B vaccine (control)
Number of subjects: 0
Study 1465689 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ‐A therapy (50 mg hydrochlorothiazide, 5 mg amiloride)
Number of subjects: 11
Study 1465689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg) plus HCTZ‐A
Number of subjects: 11
Study 1465689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (120 mg) plus HCTZ‐A
Number of subjects: 11
Study 6463312 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate (MPD)
Number of subjects: 17
Study 6463312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6463312 — intervention group
Group type: EXPERIMENTAL
Intervention: Night of habituation (N1)
Number of subjects: 17
Study 6463312 — intervention group
Group type: COMPARATOR
Intervention: Reference night (placebo) (N2)
Number of subjects: 17
Study 6463312 — intervention group
Group type: EXPERIMENTAL
Intervention: Night after 20 mg of methylphenidate (MPD) (N3)
Number of subjects: 17
Study 30652764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin
Number of subjects: 132
Study 30652764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical azithromycin
Number of subjects: 132
Study 30652764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 132
Study 29951531 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 μg/kg/h
Number of subjects: 120
Study 29951531 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 10 μg/kg/h
Number of subjects: 120
Study 29951531 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 15 μg/kg/h
Number of subjects: 120
Study 29951531 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 120
Study 27184585 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week computer-based brain training programme (Lumosity Inc.®)
Number of subjects: 0
Study 27184585 — intervention group
Group type: COMPARATOR
Intervention: General information about the brain (control group)
Number of subjects: 0
Study 25439691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg/day)
Number of subjects: 878
Study 25439691 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg/day)
Number of subjects: 878
Study 21971754 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill with optic flow
Number of subjects: 30
Study 20736233 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EDA group)
Number of subjects: 102
Study 20736233 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg
Number of subjects: 102
Study 20736233 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIAiv group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg given intravenously
Number of subjects: 102
Study 18817485 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Group condition (access to a website with an online mutual support group)
Number of subjects: 238
Study 18817485 — intervention group
Group type: COMPARATOR
Intervention: Information Only condition (access to a website containing information about student problems)
Number of subjects: 238
Study 16022053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen
Number of subjects: 50
Study 12447298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube A (Dobbhoff)
Number of subjects: 60
Study 12447298 — intervention group
Group type: COMPARATOR
Intervention: Tube B (Freka‐Trelumina)
Number of subjects: 60
Study 12447298 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper endoscopy
Number of subjects: 60
Study 10469687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (1.0 or 2.0 mg) administered once daily from stimulation day 6 onwards
Number of subjects: 46
Study 10469687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) administered during IVF cycles
Number of subjects: 46
Study 8694079 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 36
Study 8694079 — intervention group
Group type: COMPARATOR
Intervention: Paravaginal repair
Number of subjects: 36
Study 1910800 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable end‐tidal halothane concentrations of 0.5%
Number of subjects: 13
Study 1910800 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable end‐tidal halothane concentrations of 1.0%
Number of subjects: 13
Study 1910800 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 13
Study 6818076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 28
Study 6818076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 28
Study 31202686 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions targeting light exposure, fixed meal times, caffeine intake, and exercise; specific details on dosage and duration not provided.
Number of subjects: 0
Study 28157726 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation 6.4 g·d
Number of subjects: 25
Study 28157726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 26081010 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate face-to-face cognitive behavioral therapy (FtF-CBT)
Number of subjects: 173
Study 26081010 — intervention group
Group type: COMPARATOR
Intervention: Stepped Care treatment model (Psychoeducation, Internet-delivered CBT, and FtF-CBT)
Number of subjects: 173
Study 26081010 — intervention group
Group type: COMPARATOR
Intervention: Stepped Care treatment model
Number of subjects: 173
Study 24083670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) administered intravenously after ex vivo culture expansion with autologous ischemic serum
Number of subjects: 60
Study 24083670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 21355637 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK program intervention (3 individual sessions and 1 follow-up phone call)
Number of subjects: 80
Study 21355637 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK program intervention
Number of subjects: 80
Study 21355637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 19749674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-hysteroscopy with fluid distention
Number of subjects: 930
Study 17983396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90
Study 17983396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90
Study 17983396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 14579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 23
Study 14579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 23
Study 14579005 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 23
Study 14579005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11359590 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1: Detection of an audible noise
Number of subjects: 80
Study 11359590 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2: Detection of endtidal CO2 in the oral cavity
Number of subjects: 80
Study 11359590 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 3: Observation of the aneroid manometer dial as the pressure increased
Number of subjects: 80